The presence of left ventricular hypertrophy in patients with acute type A aortic dissection: weight on the postoperative clinical outcomes
Editorial

The presence of left ventricular hypertrophy in patients with acute type A aortic dissection: weight on the postoperative clinical outcomes

Wan Kee Kim1, Suk-Won Song2, Kyung-Jong Yoo3

1Department of Cardiothoracic Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea; 2Department of Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 3Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea

Correspondence to: Suk-Won Song, MD, PhD. Department of Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Enoju-ro, Gangnam-gu, Seoul 06273, Republic of Korea. Email: sevraphd@yuhs.ac.

Comment on: Zuo Y, Xing Y, Wang Z, et al. Prognostic value of left ventricular hypertrophy in postoperative outcomes in type A acute aortic dissection. J Thorac Dis 2022;14:2927-42.


Submitted Aug 31, 2022. Accepted for publication Oct 09, 2022.

doi: 10.21037/jtd-22-1195


Three decades ago, Crawford et al. reported 21% of mortality rate after acute type A aortic dissection (AD) (1). Regretfully, current large registry data still show dismal improvement in the mortality outcome (≈18%), despite a recent remarkable advance in other cardiovascular surgery (2,3). Reports from experienced centers, however, have given us optimistic results reporting 5–8% of mortality rates (4-8). Although a substantial investment would be required to lessen the mortality gap, the closing the gap may start with the rigorous evaluation. Knowing which patient will have a greater or lesser hazard to operate acute type A AD is undoubtedly an important issue.

In the journal, Zuo and his colleagues reviewed 193 patients who underwent AD repair from 2018 to 2021 in their institute (9). Scope of the study was to evaluate impacts of left ventricular hypertrophy (LVH) on clinical outcomes (55 versus 138 patients with/without LVH). The primary endpoint was a composite major outcome (CMO) including operative mortality, strokes, paraplegia, continuous renal replacement therapy (CRRT) and cardiac events. Cardiac events are indicated as low cardiac output syndrome (LCOS) plus ventricular arrhythmias. Authors performed logistic regression analyses to evaluate the influences of the presence of LVH or left ventricular mass index (LVMI) on the CMO outcome. Nomogram models were generated based on the results of multivariable risk analyses. There were significantly higher incidence of CMO (P=0.017) and mortality rate in the LVH patients. Based on multivariable risk analyses, LVH, LVMI, Penn classification, hyperlipidemia, emergency surgery and cardiopulmonary bypass (CPB) duration were applied in the nomogram models.

Although there have been previous publications reporting associations between the LVH and acute type B AD, a potential risk of LVH on the clinical outcomes after acute type A AD repair has not been adequately evaluated (10,11). Therefore, authors are to be congratulated for their interest to estimate the influence of LVH on the adverse clinical outcomes in patients who underwent acute type A AD repair. The association between LVH and AD is surely an important issue to understand the physiology of AD. Given limitation from the retrospective observational study, however, inconvenience in the evaluation of the present study exists (9). First, too many factors were included in the multivariable risk analyses for only 38 of primary outcomes. In addition, setting mortality, neurologic outcomes, CRRT, LCOS and arrhythmia altogether as one clinical endpoint seems to be too heterogenous. Second, it is regretful that there is a lack of detailed explanation on the generation of “Nomogram models”. Depending on their system, an emergent surgery has same score with a hyperlipidemia or 24 minutes of CPB which are usually regarded as minimal hazards. Moreover, patients undergoing acute type A AD repair in the non-emergent setting doesn’t mean safe because the in-hospital aortic rupture are reportedly almost 10% unless the dissected ascending aorta is replaced (12). Third, validation tests for the nomogram models are not understandable. In Fig. 3 of the study from Zuo, lines are under the half crossing line [which means 0.5 of area under curve (AUC)], but the listed AUCs were 0.825 and 0.841 for LVH and LVMI models, respectively.

Nevertheless, the core message in manuscript leads us to focus more on the baseline conditions with high degree of suspicion in the evaluation of the patients with acute type A AD. When we reviewed our institutional database from 2010 to 2018, the baseline characteristics were not significantly different from the Zuo’s manuscript (Table 1). Our in-hospital mortality rate was 6.7% (22/330). When we performed univariable logistic regression analysis, the presence of aortic rupture and malperfusion at the time of admission were significantly associated with the in-hospital mortality. The LVMI was not significantly related with the outcome (P=0.68).

Table 1

Baseline variables and risks for in-hospital death

Characteristics Acute type A aortic dissection (n=330)
Values Odd ratio 95% confidential interval P value
Age, years (mean ± SD) 59.1±13.2 1.01 0.98–1.05 0.43
Female gender, n (%) 145 (43.9) 0.89 0.33–2.35 0.82
Body mass index, kg/m2 (mean ± SD) 25.5±7.9 0.98 0.91–1.03 0.57
Smoking, n (%) 128 (38.8) 0.90 0.35–2.16 0.81
Diabetes mellitus, n (%) 34 (10.3) 0.87 0.13–3.15 0.85
Hypertension, n (%), 229 (69.4) 0.76 0.31–1.95 0.55
Renal failure, n (%) 10 (3.0) NA
Pulmonary disease, n (%) 4 (1.2) 4.84 0.23–39.7 0.18
Cerebrovascular disease, n (%) 23 (7.0) 0.62 0.04–3.19 0.65
Marfan, n (%) 3 (0.9) NA
Intramural hematoma, n (%) 58 (17.6) 0.21 0.01–1.04 0.13
Prior cardiac surgery, n (%) 63 (19.1) 0.40 0.06–1.44 0.23
Rupture at admission, n (%) 5 (1.5) 24.2 3.79–191.9 <0.001
Malperfusion, n (%) 105 (31.8) 6.56 2.61–18.8 <0.001
Left ventricular mass, g (mean ± SD) 104.9±31.5 0.99 0.98–1.01 0.68
Extent of arch surgery* 112/58/70/90 pts 0.81 0.55–1.16 0.26

*, categorically evaluated as 0 for ascending only, 1 for one-partial, 2 for two-partial and 3 for three-partial arch vessel replacements. SD, standard deviation; NA, not available; pts, patients.

Through decades, many treatment options such as extended versus limited repair, immediate versus timely surgery in the presence of malperfusion have been argued to repair the acute type A AD repair (13,14). These debates are principally based on an earnest mind to save patients with the desperate vascular condition. Although the patients visiting hospital for acute type A AD are relatively less prevalent of heart failure, the existence of LVH may add harmful effects on the postoperative outcomes, especially for patients requiring long-term cardiac ischemic time due to extensive surgery. Therefore, further evaluations based on more robust analyses in larger cohort with well-designed study are warranted.

For the publication, Wan Kee Kim drafted the manuscript, Suk-Won Song provided overall concept, and Kyung-Jong Yoo supervised (Figure 1).

Figure 1 Suk-Won Song, Kyung-Jong Yoo, Wan Kee Kim (left to right). This image is published with the participants’ consent.

Acknowledgments

Funding: None.


Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1195/coif). SWS serves as an unpaid editorial board member of Journal of Thoracic Disease from February 2021 to January 2023. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Crawford ES, Kirklin JW, Naftel DC, et al. Surgery for acute dissection of ascending aorta. Should the arch be included? J Thorac Cardiovasc Surg 1992;104:46-59. [Crossref] [PubMed]
  2. Braverman AC, Mittauer E, Harris KM, et al. Clinical Features and Outcomes of Pregnancy-Related Acute Aortic Dissection. JAMA Cardiol 2021;6:58-66. [PubMed]
  3. Ghoreishi M, Sundt TM, Cameron DE, et al. Factors associated with acute stroke after type A aortic dissection repair: An analysis of the Society of Thoracic Surgeons National Adult Cardiac Surgery Database. J Thorac Cardiovasc Surg 2020;159:2143-54.e3. [Crossref] [PubMed]
  4. Omura A, Miyahara S, Yamanaka K, et al. Early and late outcomes of repaired acute DeBakey type I aortic dissection after graft replacement. J Thorac Cardiovasc Surg 2016;151:341-8. [Crossref] [PubMed]
  5. Zhang H, Lang X, Lu F, et al. Acute type A dissection without intimal tear in arch: proximal or extensive repair? J Thorac Cardiovasc Surg 2014;147:1251-5. [Crossref] [PubMed]
  6. Yang B, Norton EL, Shih T, et al. Late outcomes of strategic arch resection in acute type A aortic dissection. J Thorac Cardiovasc Surg 2019;157:1313-21.e2. [Crossref] [PubMed]
  7. Easo J, Weigang E, Hölzl PP, et al. Influence of operative strategy for the aortic arch in DeBakey type I aortic dissection: analysis of the German Registry for Acute Aortic Dissection Type A. J Thorac Cardiovasc Surg 2012;144:617-23. [Crossref] [PubMed]
  8. Larsen M, Trimarchi S, Patel HJ, et al. Extended versus limited arch replacement in acute Type A aortic dissection. Eur J Cardiothorac Surg 2017;52:1104-10. [Crossref] [PubMed]
  9. Zuo Y, Xing Y, Wang Z, et al. Prognostic value of left ventricular hypertrophy in postoperative outcomes in type A acute aortic dissection. J Thorac Dis 2022;14:2927-42. [Crossref] [PubMed]
  10. Akutsu K, Ozaki K, Oshima S, et al. Left Ventricular Hypertrophy Is More Prevalent in Type B than Type A Aortic Dissection. Ann Thorac Cardiovasc Surg 2021;27:119-25. [Crossref] [PubMed]
  11. Taylor AP, Freeman RV, Bartek MA, et al. Left ventricular hypertrophy is a possible biomarker for early mortality after type B aortic dissection. J Vasc Surg 2019;69:1710-8. [Crossref] [PubMed]
  12. Alfson DB, Ham SW, Type B. Aortic Dissections: Current Guidelines for Treatment. Cardiol Clin 2017;35:387-410. [Crossref] [PubMed]
  13. Tanaka A, Ornekian V, Estrera AL. Limited repair with tear-oriented approach for type A aortic dissection. J Cardiovasc Surg (Torino) 2020;61:278-84. [Crossref] [PubMed]
  14. Yang B, Rosati CM, Norton EL, et al. Endovascular Fenestration/Stenting First Followed by Delayed Open Aortic Repair for Acute Type A Aortic Dissection With Malperfusion Syndrome. Circulation 2018;138:2091-103. [Crossref] [PubMed]
Cite this article as: Kim WK, Song SW, Yoo KJ. The presence of left ventricular hypertrophy in patients with acute type A aortic dissection: weight on the postoperative clinical outcomes. J Thorac Dis 2022;14(11):4212-4214. doi: 10.21037/jtd-22-1195

Download Citation